Proefschrift

Talkington, A. and Durrett, R. (2015). Estimating tumor growth rates in vivo. Bul letin of Mathematical Biology , 77(10):1934–1954. 29 Tan, K., Khor, E., Cai, J., Heng, C., and Lee, T. (2002). Automating the drug scheduling of cancer chemotherapy via evolutionary computation. Artificial Intel ligence in Medicine , 25(2):169–185. 76 Tao, Y., Guo, Q., and Aihara, K. (2010). A mathematical model of prostate tumor growth under hormone therapy with mutation inhibitor. Journal of Nonlinear Science , 20(2):219– 240. 12, 98 Thomas, F., Donnadieu, E., Charriere, G., Jacqueline, C., Tasiemski, A., Pujol, P., Renaud, F., Roche, B., Hamede, R., Brown, J., Gatenby, R., and Ujvari, B. (2018). Is adaptive therapy natural? PLoS Biology , 16(10):1–12. 97 Thomas, F., Fisher, D., Fort, P., et al. (2012). Applying ecological and evolutionary theory to cancer: a long and winding road. Evolutionary Applications , 6(1):1–10. 27 Todenho¨fer, T., Azad, A., Stewart, C., Gao, J., Eigl, B., Black, P., Joshua, A., and Chi, K. (2016). Correlation of a novel whole blood RT-PCR assay measuring AR-V7 expression with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI). 113 Tomlinson, I. (1997). Game-theory models of interactions between tumour cells. European Journal of Cancer , 33(9):1495–1500. 13, 27, 81 Trotti, A., Colevas, D., Setser, A., Rusch, V., Jaques, D., Budach, V., Langer, C., Murphy, B., Cumberlin, R., Coleman, N., et al. (2003). CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. In Seminars in Radiation Oncology , volume 13:3, pages 176–181. Elsevier. 7 Tse, S., Liang, Y., Leung, K., Lee, K., and Mok, T. (2007). A memetic algorithm for multiple- drug cancer chemotherapy schedule optimization. IEEE Transactions on Systems, Man, and Cybernetics, Part B , 37(1):84–91. 76 Ujvari, B., Roche, B., and Thomas, F. (2017). Ecology and evolution of cancer . Academic Press. 9 Venkatesan, S. and Swanton, C. (2016). Tumor evolutionary principles: how intratumor heterogeneity influences cancer treatment and outcome. American Society of Clinical Oncology Educational Book , 36:e141–e149. 5 Verbel, D., Heller, G., Kelly, W., and Scher, H. (2002). Quantifying the amount of variation in survival explained by prostate-specific antigen. Clinical Cancer Research , 8(8):2576– 2579. 97 187